News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

Use of Monoclonal Antibodies (Casirivimab + Imdevimab) for Post-Exposure Prophylaxis and the Use of Sotrovimab for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

Study Status:

Open For Enrollment

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The objective of the project is to Minimize and/or eliminate the number of adults and pediatric patients with mild to moderate COVID-19 (confirmed by positive results of direct SARS-CoV-2 viral testing) who are 12 years of age and older weighing at least 40 kg, who are at high risk for progressing to severe COVID-19 and/ or hospitalization.

Information: 

Principal Investigator
Sohail Rao, MD, MA, DPhil
Sponsor
DHR Health Institute for Research and Development
Type of Trial
Interventional
DHRHealth Institute for Research and Development
5323 S. McColl Rd., Edinburg, TX 78539
(956) 362-2390
© 2022 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram